John Giammona has over 20 years of experience working within clinical research site networks, biopharmaceutical and medical device companies, and contract research organizations. At each of these companies, Giammona consistently drove growth, built strategic alliances and biopharma partnerships, and led high-performing teams. He will help to lead ECN’s strategy and growth initiatives as the company continues to expand both its geographic footprint and full array of service offerings to the the clinical trials industry – from expanded early development/Phase 1 services through Phase 4 trials.
He began his career with Radiant Research, one of the first wholly owned site networks in the U.S., which during Giammona’s tenure reached approximately 60 clinical research sites. Most recently, he served as President and Chief Commercial Officer at KUR International, leading operations and business development for the company’s site network and biospecimen solutions business unit.
“With research clinics continuing to play an incredibly vital role in the drug development process, I am excited to join such an innovative, customer-focused, and patient-centric site network. I look forward to strengthening the company’s industry partnerships and expanding our services, including an increased focus on early clinical development,” said Giammona.
Sanjay Gulati, Principal at Surge, ECN’s private equity investor, commented, “The appointment of John to this position is critical as his strategic acumen, understanding of the client, and proven track record uniquely positions him to lead ECN’s expansion efforts within the industry.”